Literature DB >> 25269141

Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.

Delphine Abadie, Leyla Chebane, Max Bert, Geneviève Durrieu, Jean-Louis Montastruc.   

Abstract

BACKGROUND: In France, online reporting via a website is a new method for notifying adverse drug reactions (ADRs). The French Midi-Pyrénées Regional Pharmacovigilance Center (RPVC) set up in July, 2010 a Web-based ADR reporting tool in order to improve ADR reporting rate.
OBJECTIVES: To assess feasibility, use and performances of this new ADR reporting system. To evaluate the main characteristics of these online reports.
METHODS: In a retrospective study, we evaluated characteristics (numbers, ADR reporting and file processing times, type of reporters, suspected drugs, "seriousness" and nature of ADRs) of online notifications reported to the RPVC between July 7(th), 2010 (first online notification) and December 31(th), 2011. We performed comparisons to a random sample of "conventional" notifications, i.e. spontaneously reported to the RPVC via traditional tools (post, fax, e-mail or telephone) during the same period.
RESULTS: The total number of online reports was 312 over the 18-month period. There was a 45% increase in numbers of reports from ambulatory healthcare professionals after the implementation of the new reporting tool. Online reports were transmitted to the French Medicine Agency on average almost one month (26 days) earlier than "conventional" ones. This difference was mainly due to a faster ADR notification process via the online form (on average, the reporting period was decreased by 19 days with the new tool). In comparison to "conventional" notifications, online reports came more often from ambulatory healthcare professionals, and involved more frequently neuropsychiatric drugs and neuropsychiatric ADRs. None difference was observed for "seriousness" of ADRs.
CONCLUSIONS: It is feasible to deploy an online ADR reporting system used by health professionals in current practice. We underline the efficiency of this new online reporting tool for increasing ADRs reporting. Moreover, this is the first published study demonstrating that an online reporting tool can help to save time on the ADR reporting period and file processing, which is essential to generate early safety signals.
© 2014 Société Française de Pharmacologie et de Thérapeutique.

Mesh:

Year:  2014        PMID: 25269141     DOI: 10.2515/therapie/2014035

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  9 in total

1.  Barriers to the success of an electronic pharmacovigilance reporting system in Kenya: an evaluation three years post implementation.

Authors:  Oscar O Agoro; Sarah W Kibira; Jenny V Freeman; Hamish S F Fraser
Journal:  J Am Med Inform Assoc       Date:  2018-06-01       Impact factor: 4.497

2.  Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting.

Authors:  François Montastruc; Haleh Bagheri; Isabelle Lacroix; Christine Damase-Michel; Leila Chebane; Vanessa Rousseau; Emilie Jouanjus; Maryse Lapeyre-Mestre; Geneviève Durrieu; Jean-Louis Montastruc
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

3.  Assessment of Knowledge, Attitude and Practice of Adverse Drug Reaction Reporting Among Healthcare Professionals working in Primary, Secondary and Tertiary Healthcare Facilities in Ekiti State, South-West Nigeria.

Authors:  Theophilus A Adegbuyi; Joseph O Fadare; Ebisola J Araromi; Abayomi O Sijuade; Iyanu Bankole; Ilesanmi K Fasuba; Rachel A Alabi
Journal:  Hosp Pharm       Date:  2020-09-18

4.  Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial.

Authors:  Ronald Kiguba; Norah Mwebaza; Ronald Ssenyonga; Helen Byomire Ndagije; Victoria Nambasa; Cordelia Katureebe; Kenneth Katumba; Phil Tregunno; Kendal Harrison; Charles Karamagi; Kathryn A Scott; Munir Pirmohamed
Journal:  BMJ Open       Date:  2022-07-01       Impact factor: 3.006

5.  Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.

Authors:  Geneviève Durrieu; Julien Jacquot; Mathilde Mège; Emmanuelle Bondon-Guitton; Vanessa Rousseau; François Montastruc; Jean-Louis Montastruc
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

Review 6.  How to promote adverse drug reaction reports using information systems - a systematic review and meta-analysis.

Authors:  Inês Ribeiro-Vaz; Ana-Marta Silva; Cristina Costa Santos; Ricardo Cruz-Correia
Journal:  BMC Med Inform Decis Mak       Date:  2016-03-01       Impact factor: 2.796

7.  Public-private partnership (3Ps) in ensuring safe use of medicines: An Indian experience.

Authors:  Vivekanandan Kalaiselvan; Shatrunajay Shukla; Shubhang Arora; Tarani Prakash Shrivastava; Rajeev Singh Raghuvanshi
Journal:  Front Public Health       Date:  2022-08-11

8.  Promoting adverse drug reaction reporting: comparison of different approaches.

Authors:  Inês Ribeiro-Vaz; Cristina Costa Santos; Ricardo Cruz-Correia
Journal:  Rev Saude Publica       Date:  2016-05-03       Impact factor: 2.106

Review 9.  Patient Participation and the Use of Ehealth Tools for Pharmacoviligance.

Authors:  Joëlle Berrewaerts; Laure Delbecque; Pierre Orban; Martin Desseilles
Journal:  Front Pharmacol       Date:  2016-04-11       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.